Anti-HLA-DRA antibody [1D09C3] {FITC} (STJA0028844)

SKU:
STJA0028844
€206.88 - €289.38
Free Shipping
Processing The item has been added

Host: Mouse
Applications: FC
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description : Mouse monoclonal antibody anti-Hla Class Ii Histocompatibility antigen-Dr Alpha Chain is suitable for use in Flow Cytometry research applications.
Clonality : Monoclonal
Clone ID : 1D09C3
Conjugation: FITC
Isotype: IgG1k
Formulation: 0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.
Purification: Purified
Concentration: 0.5 mg/mL
Storage Instruction: Store at 4°C for 12 months. Protect from light. Do not freeze.
Gene Symbol: HLA-DRA
Gene ID: 3122
Uniprot ID: DRA_HUMAN
Post Translational Modifications Ubiquitinated by MARCHF1 or MARCHF8 at Lys-244 leading to down-regulation of MHCII. When associated with ubiquitination of the beta chain at 'Lys-254', the down-regulation of MHCII may be highly effective.
Function An alpha chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the beta chain HLA-DRB, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DR-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells. Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes. In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins. Presents peptides derived from intracellular proteins that are trapped in autolysosomes after macroautophagy, a mechanism especially relevant for T cell selection in the thymus and central immune tolerance. The selection of the immunodominant epitopes follows two processing modes: 'bind first, cut/trim later' for pathogen-derived antigenic peptides and 'cut first, bind later' for autoantigens/self-peptides. The anchor residue at position 1 of the peptide N-terminus, usually a large hydrophobic residue, is essential for high affinity interaction with MHCII molecules.
Protein Name Hla Class Ii Histocompatibility Antigen - Dr Alpha Chain
Mhc Class Ii Antigen Dra
Database Links Reactome: R-HSA-202424
Reactome: R-HSA-202427
Reactome: R-HSA-202430
Reactome: R-HSA-202433
Reactome: R-HSA-2132295
Reactome: R-HSA-389948
Reactome: R-HSA-877300
Cellular Localisation Cell Membrane
Single-Pass Type I Membrane Protein
Endoplasmic Reticulum Membrane
Early Endosome Membrane
Late Endosome Membrane
Lysosome Membrane
Autolysosome Membrane
The Mhcii Complex Transits Through A Number Of Intracellular Compartments In The Endocytic Pathway Until It Reaches The Cell Membrane For Antigen Presentation
Component Of Immunological Synapses At The Interface Between T Cell And Apc
Alternative Antibody Names Anti-Hla Class Ii Histocompatibility Antigen - Dr Alpha Chain antibody
Anti-Mhc Class Ii Antigen Dra antibody
Anti-HLA-DRA antibody
Anti-HLA-DRA1 antibody

Information sourced from Uniprot.org